ZELLSUSPENSION UND VERWENDUNG DAVON

Patent europeic · EP3896152 · En vigur

Inscripziun en il register

Numer da publicaziun
EP3896152
Numer da la dumonda
EP21156318
Gener
Patent europeic cun effect per la Svizra ed il Liechtenstein
Status
En vigur
Scrittira da patent
Concedì
Annunzià
14-03-2013
Publitgà
20-10-2021
Concedì
31-12-2025
La protecziun finescha il pli tard
13-03-2033
Proxima taxa annuala scadenta
31-03-2027
Classas IPC
C12N 5/02 (2006.01)
C12N 5/071 (2010.01)
A61L 27/38 (2006.01)
A61L 27/60 (2006.01)
A61L 27/54 (2006.01)
Prioritad
US 201261614115 P 22.03.2012
US 201261614112 P 22.03.2012
Derivà da
EP13764726
Lingua da l’annunzia
englais
Funtauna
Swissreg

Istorgia

Quai che l’Institut federal da la proprietad intellectuala ha publitgà davart quest titel, il pli nov l’emprim.

  1. 01-04-2026

    Midada

    Published in Swissreg on 01.04.2026

  2. 05-01-2026

    Represchentant inscrit

    Representative
    BOVARD AG, Optingenstrasse 16, 3013 Bern

    Published in Swissreg on 05.01.2026

  3. 31-12-2025

    Concedì

    Specification status
    Non-published patent application → Granted patent
    Status of protective title
    Initiated → Active

    Published in Swissreg on 31.12.2025

Partidas

Possessur

AVITA Medical Americas, LLC

28159 Avenue Stanford, Suite 200, Valencia, CA 91355, US

Represchentant

Bovard AG

BOVARD AG

Optingenstrasse 16, 3013 Bern

Inventur

QUICK, Andrew

Valencia, CA California 91355, US

DOLPHIN, William

Topanga, CA California 90290, US

Il register numna mintga partida cun num ed adressa. In possessur u in represchentant vegn collià cun in’organisaziun, sch’exact ina unitad giuridica dal register da commerzi porta ses num; la via d’ina partida betg enconuschida uschia na vegn betg mussada qua.